⚡What does Johnson & Johnson do, in 30 seconds?
Johnson & Johnson makes prescription medicines and medical devices, in two business segments called Innovative Medicine and MedTech 20. It sold $94.2bn ✓ in FY2025, the year to 28 December 2025. Medicines made up 64% ✓ of that, and devices 36% ✓.
📱What does Johnson & Johnson sell?
Johnson & Johnson has two businesses: medicines, which bring in most of the money, and medical devices. Here is what each one sells and who buys it.
Innovative Medicine
Prescription medicines for cancer, immune diseases, brain disorders, high blood pressure in the lungs, infections, and heart and metabolism 1. The biggest is DARZALEX, for multiple myeloma, at about 15.0% of company revenue in fiscal 2025 12. Next came STELARA, at about 6.5% 12, and TREMFYA, at about 5.5% 12. Both treat psoriasis and the gut diseases Crohn's disease and ulcerative colitis 12. CARVYKTI is a cell therapy for multiple myeloma that has come back or stopped responding to treatment 1. In April 2025 the company bought Intra-Cellular Therapies, maker of CAPLYTA, for $14.5 billion 3. This segment brought in $60.4bn ✓ in FY2025.
👥 Johnson & Johnson sells them to retailers, wholesalers, distributors, hospitals and health workers for prescription use 1.
MedTech
Medical devices in four areas: heart, bones and joints, surgery and vision 5. The heart business includes products for heart rhythm problems, Abiomed heart pumps and Shockwave tools for hardened arteries 5. Vision sells ACUVUE contact lenses and TECNIS lenses used in cataract surgery 5. In the third quarter of fiscal 2026, surgery sold $2.53 billion, bones and joints $2.35 billion, heart $2.31 billion and vision $1.46 billion 6. This segment brought in $33.8bn ✓ in FY2025.
👥 Doctors, hospitals, eye care professionals and clinics 5.
How the mix has shifted
Where the customers are
The United States is by far the biggest market, at 57% ✓ of sales in FY2025. Europe added 23% ✓, and Asia Pacific and Africa 15% ✓. The Americas outside the US made up the last 5% ✓.
💸How does Johnson & Johnson make money?
Follow the money: what customers pay for, what it costs to make, and what is left as profit.
Johnson & Johnson sold $94.2bn ✓ of medicines and devices in FY2025. Making them cost $30.3bn ✓. What is left is gross profit, the money kept after paying for what was sold. That came to $63.9bn ✓.
Next come the costs of running the company. Research and development took $14.7bn ✓, and sales, marketing and admin took $23.7bn ✓. Other operating costs took $0.3bn ✓. What remains is operating profit, the profit from the main business, which was $25.3bn ✓. Other income and gains then added $7.3bn ✓, and tax took $5.8bn ✓. That left net income of $26.8bn ✓. Put simply, out of every hundred dollars of sales, the company kept about $29 ✓ as profit. That includes about $8 ✓ added on top from other income and gains.
Out of every $100 customers paid in FY2025…
Interest, investment gains and other income added +$8 for every $100 of sales, so the slices above add up to $108, well over $100.
⏱️ Johnson & Johnson by the clock
Spread the FY2025 totals evenly over its 364 days and you get this. Source: JOHNSON & JOHNSON 10-K [7].
📈How is Johnson & Johnson doing?
Johnson & Johnson is growing steadily. Sales reached $94.2bn ✓ in FY2025, up 6.0% ✓ on FY2024. Those FY2025 sales include those of Intra-Cellular Therapies, which the company bought on 2 April 2025 3. Copies of STELARA, called biosimilars, cut the company's worldwide sales growth, before currency moves, by about 6.2 percentage points in fiscal 2025 12. Operating margin was 26.8% ✓, and free cash flow was $19.7bn ✓. Sales rose in all 4 ✓ of the last 4 ✓ fiscal years, from FY2022 to FY2025.
The latest four quarters, to 27 September 2026, brought in $99.3bn ✓, up 7.8% ✓ on the four quarters before. The latest four quarters include Intra-Cellular Therapies throughout, while the four before include it only from 2 April 2025 3. Free cash flow over those quarters was $20.6bn ✓. In the third quarter of fiscal 2026, sales were $25.4 billion, up 5.9% on a year earlier 26. Diluted earnings per share in that quarter were $0.09, against $2.12 a year earlier 26. That reflected a one-time charge for the proposed talc settlement and for the Firefly Bio and Sail Biomedicines deals 26. On 13 October 2026, the company raised its 2026 forecast to sales of $101.0 billion to $101.4 billion 26.
The company has more borrowings than cash. On 27 September 2026 it had $17.2bn ✓ of cash and investments and $44.7bn ✓ of borrowings.
📝 The report card
Johnson & Johnson earns top marks for cash and steadiness, a good mark for profit, a middle mark for growth and a failing mark for its balance sheet. Every company is graded on the same fixed scale, so an A means the same thing on every page. The strip shows where Johnson & Johnson (orange) and its 4 peers land; further right is better.
Growth
Johnson & Johnson's sales grew 5.6% ✓ a year over its last three fiscal years, which earns a C ✓ on the fixed scale. Eli Lilly grew 31.7% ✓ a year, an A ✓. Pfizer's figure was -14.8% ✓, an F ✓, as its sales shrank.
Why this measure? (higher is better)
Growing sales is the engine of a business. Mature giants rarely grow fast, so 5% a year already earns a C.
Profitability
Over the last three years combined, Johnson & Johnson kept 25.1% ✓ of sales as operating profit, which earns a B ✓. Eli Lilly kept 31.6% ✓, an A ✓. Merck kept 24.4% ✓, also a B ✓.
Why this measure? (higher is better)
Operating margin is the share of each sales dollar left after running the business. Software and platforms often clear 30%; hardware makers usually sit below 10%.
Cash generation
Over the last three years combined, Johnson & Johnson turned 21.5% ✓ of sales into free cash flow, which earns an A ✓. In FY2024 the figure was 22.3% ✓, and in FY2025 it was 20.9% ✓. AbbVie did better at 33.6% ✓, also an A ✓. Eli Lilly turned 9.4% ✓ into free cash flow, a D ✓.
Why this measure? (higher is better)
Free cash flow is the cash left after paying for factories, data centres and equipment. It funds dividends, buybacks and new bets.
Balance sheet
At the end of FY2025, Johnson & Johnson's cash and investments minus its borrowings (leases and stakes in other companies not counted) equalled -31.7% ✓ of a year's sales. That is just past the -30% line, so it earns an F ✓. The net cash figure was -$29.8bn ✓ at the end of FY2025. Eli Lilly's figure was -54.1% ✓, also an F ✓, and AbbVie's was -91.9% ✓, an F ✓.
Why this measure? (higher is better)
More cash than debt gives a company room to ride out bad years. Some debt is normal; a lot of it makes a company fragile.
Steadiness
Johnson & Johnson's yearly growth rates barely move. Over its 4 ✓ years of growth figures, from FY2022 to FY2025, the standard deviation is 2.2% ✓, which earns an A ✓. Measured over up to 10 years, Merck's figure is 8.5% ✓, a C ✓, and Pfizer's is 41.5% ✓, an F ✓.
Why this measure? (lower is better)
Steady growers are easier to plan around. Big swings mean sales depend on product cycles, the economy or one-off events.
🧑🏫 How the grades work
- Same scale for everyone. Each measure has fixed cut-offs (shown under each strip). Clear the A line and you get an A, whatever your peers do.
- Three years together. Profitability and cash generation add up the last three fiscal years before dividing, so one unusual year counts for less than it would on its own (a year much bigger than the others still weighs most).
- Peers for context. The rank shows how Johnson & Johnson compares with the group. Companies within 0.1 percentage point share a rank.
- Same source. Every company's figures come from its own latest annual report (10-K), so fiscal years end in different months.
- Judgement, openly stated. The cut-offs are QuantVantage.ai's view of what good looks like for a large, established company. They are not a forecast or a recommendation.
5 years at a glance
Where the cash goes
Johnson & Johnson handed back most of its free cash flow to shareholders in FY2024 and FY2025. In FY2024, buybacks and dividends came to 72% ✓ of free cash flow. In FY2025 it paid $12.4bn ✓ of dividends and spent $6.0bn ✓ on buybacks. Together that was 93% ✓ of the year's free cash flow. In April 2026 it raised its quarterly dividend by 3.1% to $1.34 a share, its 64th yearly increase in a row 23.
🧮Ratios 101: what are Johnson & Johnson's key financial ratios?
Ratios shrink Johnson & Johnson's big numbers into easy comparisons with other drug makers. A ratio divides one number by another so companies of any size can be compared. Each card shows the formula with Johnson & Johnson's real FY2025 numbers, the peer median and the trend.
💰 Profitability: how much of each sale is kept?
Gross margin
What is left from each sale after paying to make the product or deliver the service.
👉 Johnson & Johnson keeps 67.9% ✓ of sales as gross profit, below the 74.6% ✓ peer median. Eli Lilly is highest at 83.0% ✓.
📏 Rule of thumb: Above 40% usually signals pricing power or a big software or services mix.
Operating margin
What is left after also paying for research, marketing and running the company.
👉 Its operating margin of 26.8% ✓ is below the 30.1% ✓ peer median. Eli Lilly is highest at 40.4% ✓.
📏 Rule of thumb: Above 20% is strong for a large company.
Net margin
The bottom line: profit after interest and taxes, per dollar of sales.
👉 Net margin of 28.5% ✓ is above operating margin in FY2025, because $7.3bn ✓ of other income and gains was added. It beats the 20.2% ✓ peer median.
📏 Rule of thumb: Above 15% is strong; one-off tax items can move it in a single year.
Return on equity (ROE)
Profit earned for each dollar that shareholders have left in the company.
👉 ROE of 32.9% ✓ sits just under the 34.7% ✓ peer median, on $81.5bn ✓ of shareholders' equity.
📏 Rule of thumb: Around 15% or more is good, but buybacks shrink equity and can make ROE look huge.
⚙️ Efficiency: how hard do the assets work?
Return on assets (ROA)
Profit earned from everything the company owns, however it was paid for.
👉 ROA of 13.5% ✓ beats the 8.5% ✓ peer median: profit was high for the $199.2bn ✓ the company owns.
📏 Rule of thumb: Above 10% is strong; banks and factories usually earn less.
Asset turnover
Dollars of sales squeezed out of each dollar of assets.
👉 Sales equal 0.5x ✓ the value of everything the company owns, the same as the 0.5x ✓ peer median.
📏 Rule of thumb: Retailers often top 2x; asset-heavy businesses can sit below 0.5x.
Inventory days
How many days of products sit in warehouses before they are sold.
👉 Johnson & Johnson holds 171 ✓ days of stock, fewer than the peer median of 195 ✓ days. Eli Lilly holds 454 ✓ days.
📏 Rule of thumb: Fewer days means less cash tied up and less risk of products going stale.
🛟 Safety: could it survive a bad year?
Current ratio
Can short-term assets (cash, money owed by customers, stock) pay the bills due within a year?
👉 A current ratio of 1.0x ✓ means short-term assets just cover the bills: $55.6bn ✓ of current assets against $54.1bn ✓ due within a year.
📏 Rule of thumb: Above 1.0x is the classic comfort line, but cash-rich giants can run below it on purpose.
Debt to equity
How much the company has borrowed for each dollar shareholders have in it.
👉 Debt is 0.6x ✓ shareholders' equity, below the 0.9x ✓ peer median.
📏 Rule of thumb: Below 1.0x is conservative. Like ROE, it can rise when buybacks shrink equity, even if debt has not changed.
Interest cover
How many times over operating profit could pay the year's interest bill.
👉 Operating profit covers interest 26.0x ✓, well above the 11.2x ✓ peer median.
📏 Rule of thumb: Above 5x is comfortable; below 2x is a warning sign.
💵 Cash and owners: where does the money end up?
Cash conversion
Does reported profit turn into real cash? Free cash flow is operating cash minus capital spending.
👉 Free cash flow was 0.7x ✓ net income in FY2025, a little below the 0.9x ✓ peer median.
📏 Rule of thumb: Near or above 1.0x means profits are backed by cash.
R&D intensity
How much of each sales dollar goes into inventing future products.
👉 Johnson & Johnson spends 15.6% ✓ of sales on research, below the 18.6% ✓ peer median. Merck spends the most, at 24.3% ✓.
📏 Rule of thumb: Tech companies often spend 10% to 20%; more is not always better if it does not pay off.
Stock pay
Pay given to staff in shares instead of cash. It is a real cost to owners because it adds shares.
👉 Stock pay is 1.4% ✓ of sales, close to the 1.3% ✓ peer median.
📏 Rule of thumb: Under 5% of sales is modest for a tech company.
Shareholder payout
How much of the year's profit was handed back to owners.
👉 The company handed back 68.4% ✓ of FY2025 profit as dividends and buybacks, below the 99.2% ✓ peer median.
📏 Rule of thumb: Above 100% means it returned more than it earned, using cash savings or debt.
Ratios use fiscal-year-end balance sheet values. Inputs are shown rounded, so dividing them can differ from the result in the last digit. A peer median leaves out peers that do not report the inputs, or where the ratio means nothing (for example, negative shareholders' equity). Rules of thumb are general guides from QuantVantage.ai, not hard limits. No share-price ratios (like price-to-earnings) are shown on this page.
🥊Who are Johnson & Johnson's competitors?
Johnson & Johnson's medicines meet the big drug makers head on. Eli Lilly and AbbVie sell rivals to TREMFYA 112131718. Merck competes in pulmonary arterial hypertension, high blood pressure in the lungs 11214, and Pfizer in multiple myeloma 1516.
| Company | Where they compete | Revenue | Growth/yr (3y) | Op. margin | FCF margin |
|---|---|---|---|---|---|
| Johnson & Johnson (JNJ, FY2025) | Prescription medicines and medical devices | $94.2bn | 5.6% | 26.8% | 20.9% |
| Eli Lilly (LLY, FY2025) | Taltz against TREMFYA in plaque psoriasis and psoriatic arthritis 11213 | $65.2bn | 31.7% | 40.4% | 13.8% |
| Merck (MRK, FY2025) | Winrevair against OPSUMIT and OPSYNVI in pulmonary arterial hypertension 11214 | $65.0bn | 3.1% | 34.2% | 19.0% |
| Pfizer (PFE, FY2025) | Elrexfio against TECVAYLI in multiple myeloma 1516 | $62.6bn | -14.8% | 26.1% | 14.5% |
| AbbVie (ABBV, FY2025) | Skyrizi against TREMFYA in psoriasis, psoriatic arthritis, Crohn's disease and ulcerative colitis 1718 | $61.2bn | 1.8% | 24.6% | 29.1% |
The company says its businesses compete on cost, new technology, patents, how well products work, price, supply and insurance payment 20. STELARA faced growing competition from biosimilar copies in the third quarter of fiscal 2026 6. In surgery, Advanced Surgery sales fell in the third quarter of fiscal 2026, partly because of competition in surgical staplers and energy devices 6.
🧭Johnson & Johnson SWOT: strengths, weaknesses, opportunities and threats
💪 Strengths
🩹 Weaknesses
- STELARA sales fell 54.4% to $716 million in the third quarter of fiscal 2026, as biosimilar competition grew 6.
- US generic copies of OPSUMIT arrived late in the second quarter of fiscal 2026, and OPSUMIT and OPSYNVI sales fell 35.7% in the third quarter of fiscal 2026 622.
- DARZALEX made up about 15.0% of company revenue in fiscal 2025 12. That year the company paid Genmab royalties of 12% to 20% of DARZALEX net sales 2.
- On 27 September 2026, net cash was -$27.4bn ✓: borrowings were bigger than cash and investments.
🚀 Opportunities
- The FDA approved ICOTYDE, a once-a-day medicine for plaque psoriasis taken by mouth, in the first quarter of fiscal 2026 25.
- CARVYKTI sales rose 35.5% and TECVAYLI sales rose 76.6% in the third quarter of fiscal 2026 6.
- The OTTAVA surgical robot won US FDA authorization in the third quarter of fiscal 2026 26. The company calls it the world's first soft-tissue surgical robot built into the operating table 26.
- Shockwave sales rose 16.8% to $325 million in the third quarter of fiscal 2026 6.
⚠️ Threats
- On 27 September 2026, about 76,500 US plaintiffs had claims over talc body powders, and the talc reserve was about $9.0 billion 27.
- The US government sets Medicare prices for XARELTO, STELARA and IMBRUVICA from 2026 28. ERLEADA, a prostate cancer medicine, is on Medicare's selected drug list for 2028 128.
- The two Genmab patent families behind DARZALEX expire in the US in 2029 2.
- In China, government bulk buying, called volume-based procurement, partly caused a fall in Advanced Surgery sales in the third quarter of fiscal 2026 6.
🏰Does Johnson & Johnson have a moat?
Why 3?
Johnson & Johnson's companies sell products under trademarks they register in each country 2. Its ACUVUE OASYS 1-Day contact lenses, with price rises, drove lens growth in the third quarter of fiscal 2026 6. Robert Wood Johnson, a member of the founding family and chairman from 1932 to 1963, wrote the company's Our Credo in 1943 19. But the company says its businesses compete on cost, new technology, patents, results, price, supply and insurance payment 20.
Why 3?
Knee sales growth came partly from extra sales that its VELYS robot-assisted system brought in, in fiscal 2025 and in the third quarter of fiscal 2026 126. Its heart business sells Abiomed heart pumps and Shockwave tools for hardened arteries 5. Still, Advanced Surgery sales fell in the third quarter of fiscal 2026, partly because of competition in surgical staplers and energy devices 6.
Why 1?
The company says its businesses compete on cost, new technology, patents, results, price, supply and insurance payment 20.
Why 3?
Its companies do business in virtually all countries of the world 20. It had about 140,800 employees on 28 December 2025 21. It spent $14,665 million on research in fiscal 2025, or 15.6% of sales 12. In the third quarter of fiscal 2026, China's government bulk buying partly caused a fall in Advanced Surgery sales 6.
Why 4?
Its companies own or license many patents on products, uses, formulas and ways of making them 2. The two Genmab patent families behind DARZALEX expire in the US in 2029, and a TREMFYA patent family is projected to expire there in 2031 2. Protection does run out: STELARA copies cut the company's worldwide sales growth, before currency moves, by about 6.2 points in fiscal 2025 12. STELARA sales fell 54.4% in the third quarter of fiscal 2026 6, and US generic copies of OPSUMIT arrived late in the second quarter of fiscal 2026 622. OPSUMIT and OPSYNVI sales fell 35.7% in the third quarter 622.
A moat is what keeps rivals from taking a company's customers and profits. Scores are QuantVantage.ai's judgement (5 = strongest), set with the same rubric on every explainer (orange is Johnson & Johnson; grey dots are peers).
🔭What should you watch next?
Enterprise Business Review
In April 2026, the company said it planned an Enterprise Business Review for 8 December 2026 25.
A 53-week fiscal 2026
Fiscal 2026 has 53 weeks instead of the usual 52, which adds shipping days compared with fiscal 2025 35.
Talc settlement
On 27 July 2026, the company announced a deal with the lead plaintiff law firms to resolve the ovarian talc lawsuits, with a $5.5 billion commitment 30. Among other conditions, the proposed deal needs at least 95% of the remaining claims to take part, and it does not cover mesothelioma claims 2730. The first payment, of no more than $3 billion, would be due in 2027 30.
More generic rivals
The company says generic copies of UPTRAVI in the US and Europe, and of OPSUMIT in Europe, could arrive in 2027 22.
📚Learn the words
❓Frequently asked questions about Johnson & Johnson
How does Johnson & Johnson make money?
Johnson & Johnson makes most of its money from prescription medicines. In FY2025, Innovative Medicine brought in $60.4bn ✓ and MedTech $33.8bn ✓.
What is Johnson & Johnson's biggest product?
DARZALEX, a treatment for multiple myeloma, was the biggest product in fiscal 2025, at about 15.0% of company revenue 12.
What happened to Johnson & Johnson's consumer health business?
Its former Consumer Health business became a separate company, Kenvue 29. Johnson & Johnson separated it in August 2023 30, and has owned no Kenvue shares since 17 May 2024 29.
What is the talc lawsuit about?
The lawsuits are about body powders that contained talc. On 27 September 2026, about 76,500 US plaintiffs had claims over them, and the talc reserve was about $9.0 billion 27. In July 2026 the company announced a proposed $5.5 billion deal to resolve the ovarian talc lawsuits 3027. It stopped selling talc-based baby powder worldwide in 2023 30.
Is Johnson & Johnson's revenue still growing?
Johnson & Johnson's revenue is still growing. Sales rose 6.0% ✓ in FY2025, including Intra-Cellular Therapies from 2 April 2025 3. Sales over the four quarters to 27 September 2026 were up 7.8% ✓ on the four quarters before.
How much does Johnson & Johnson spend on research?
It spent $14.7bn ✓ on research and development in FY2025. That was 15.6% ✓ of sales, or about $40m ✓ a day.
Does Johnson & Johnson pay a dividend?
Johnson & Johnson pays a quarterly dividend. In April 2026 it raised it by 3.1% to $1.34 a share, its 64th yearly increase in a row 23. It paid $12.4bn ✓ of dividends in FY2025.
🎮Play: higher or lower, then test yourself
Figures come from each company's latest annual report (10-K); fiscal years end in different months. Sources: [7] [8] [10] [9] [11].
🧠 Test yourself
5 quick questions. Score: 0 / 5
1. About how much of Johnson & Johnson's sales came from medicines in FY2025?
2. In what year was Johnson & Johnson founded?
3. What happened to Johnson & Johnson's consumer health business?
4. How many years in a row has Johnson & Johnson raised its dividend, as of April 2026?
5. What is a biosimilar?
🔎Sources and method
Every figure comes from a source listed here or is calculated from those sources (marked ✓). Company financials come from the reports each company files with the SEC (10-K annual and 10-Q quarterly reports). Peer grades rank the same measures across the company and its peers. This page contains no share-price data and no valuation.
- Johnson & Johnson Form 10-K for fiscal year 2025 — Item 1 Innovative Medicine segment: therapeutic areas, customers, key products (accessed 2026-11-04)
- Johnson & Johnson Form 10-K for fiscal year 2025 — Item 1 Patents: largest products' share of 2025 revenue, patent expiry, biosimilars (accessed 2026-11-04)
- Johnson & Johnson Form 10-Q for the fiscal third quarter of 2026 — Note 10 Acquisitions: Halda, Intra-Cellular, Firefly Bio, Sail Biomedicines (accessed 2026-11-04)
- Johnson & Johnson (JNJ) Form 10-K for fiscal year 2025, filed 2026-02-11 — revenue and cost of sales by product, segment and geography (accessed 2026-11-04)
- Johnson & Johnson Form 10-K for fiscal year 2025 — Item 1 MedTech segment: franchises, customers; planned Orthopaedics separation (accessed 2026-11-04)
- Johnson & Johnson Form 10-Q for the fiscal third quarter of 2026 — MD&A: Q3 2026 sales by therapeutic area, product and MedTech franchise (accessed 2026-11-04)
- SEC EDGAR companyfacts: Johnson & Johnson (JNJ) — annual 10-K facts (accessed 2026-11-04)
- SEC EDGAR companyfacts: ELI LILLY & Co (LLY) — annual 10-K facts (accessed 2026-11-04)
- SEC EDGAR companyfacts: PFIZER INC (PFE) — annual 10-K facts (accessed 2026-11-04)
- SEC EDGAR companyfacts: Merck & Co., Inc. (MRK) — annual 10-K facts (accessed 2026-11-04)
- SEC EDGAR companyfacts: AbbVie Inc. (ABBV) — annual 10-K facts (accessed 2026-11-04)
- Johnson & Johnson Form 10-K for fiscal year 2025 — Item 7 MD&A: 2025 sales by region and product, STELARA biosimilar impact, franchise drivers, research and development expense (accessed 2026-11-04)
- Eli Lilly and Company Form 10-K for fiscal year 2025 — Item 1 product list (Taltz, Omvoh) and 2025 revenue by product (accessed 2026-11-04)
- Merck & Co. Form 10-K for fiscal year 2025 — Item 1 Winrevair description and 2025 product sales table (accessed 2026-11-04)
- Johnson & Johnson Form 10-K for fiscal year 2025 — Tecvayli 2025 worldwide sales and multiple myeloma use (accessed 2026-11-04)
- Pfizer Form 10-K for fiscal year 2025 — Note 17C: significant customers and revenues by product for 2023-2025 (accessed 2026-11-04)
- AbbVie Form 10-K for fiscal year 2025 — Item 7 recent events (U.S. government agreement, Inflation Reduction Act selections) and net revenues by product 2023-2025 (accessed 2026-11-04)
- Johnson & Johnson Form 10-K for fiscal year 2025 — Tremfya uses and 2025 worldwide sales; Imbruvica collaboration with Pharmacyclics (an AbbVie company) (accessed 2026-11-04)
- Johnson & Johnson: Our Credo — Origin of Our Credo (1943) (accessed 2026-11-04)
- Johnson & Johnson Form 10-K for fiscal year 2025 — Item 1 overview: employees, incorporation, holding company, two segments (accessed 2026-11-04)
- Johnson & Johnson Form 10-K for fiscal year 2025 — Item 1 Employees and human capital: employee and FTE counts (accessed 2026-11-04)
- Johnson & Johnson Form 10-Q for the fiscal third quarter of 2026 — MD&A: Orthopaedics separation timing; SIMPONI, UPTRAVI and OPSUMIT competition outlook; Stelara impact (accessed 2026-11-04)
- Johnson & Johnson press release: 64th consecutive year of dividend increase (Form 8-K exhibit 99.3, April 14, 2026) — Dividend increase history (accessed 2026-11-04)
- SEC EDGAR companyfacts: Johnson & Johnson (JNJ) — balance sheet at 2026-09-27 (accessed 2026-11-04)
- Johnson & Johnson press release: Q1 2026 results (Form 8-K exhibit 99.1, April 14, 2026) — Q1 2026 approvals; planned Enterprise Business Review date (accessed 2026-11-04)
- Johnson & Johnson press release: Q3 2026 results (Form 8-K exhibit 99.1, October 13, 2026) — Q3 2026 sales, EPS, 2026 guidance, notable announcements (accessed 2026-11-04)
- Johnson & Johnson Form 10-Q for the fiscal third quarter of 2026 — Note 11 Legal proceedings: matters concerning talc (accessed 2026-11-04)
- Johnson & Johnson Form 10-K for fiscal year 2025 — Item 1 Regulation: Inflation Reduction Act selected drugs (accessed 2026-11-04)
- Johnson & Johnson Form 10-K for fiscal year 2025 — Note 21 Kenvue separation and discontinued operations (accessed 2026-11-04)
- Johnson & Johnson press release: proposed resolution of ovarian talc litigation (Form 8-K exhibit 99.1, July 27, 2026) — Talc proposed resolution terms; baby powder discontinued; Kenvue indemnity (accessed 2026-11-04)
- SEC EDGAR companyfacts: Johnson & Johnson (JNJ) — quarterly 10-Q/10-K facts (accessed 2026-11-04)
- Johnson & Johnson Form 10-K for fiscal year 2025 — Executive officers of the registrant: Joaquin Duato (accessed 2026-11-04)
- Johnson & Johnson: Our heritage — Founding year and cofounders (accessed 2026-11-04)
- Johnson & Johnson Form 10-K for fiscal year 2025 — Cover page: principal executive offices (accessed 2026-11-04)
- Johnson & Johnson Form 10-K for fiscal year 2025 — Note 1 Annual closing date: fiscal year definition, 53-week fiscal 2026 (accessed 2026-11-04)
- Johnson & Johnson press release: Q4 and full-year 2025 results (Form 8-K exhibit 99.1, January 21, 2026) — Q4 2025 notable announcements: Halda acquisition, Orthopaedics separation intent, OTTAVA submission (accessed 2026-11-04)